Peripheral benzodiazepine receptor (PBR) ligand cytotoxicity unrelated to PBR expression

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Peripheral-type benzodiazepine receptor (PBR) ligands show potential as chemotherapeutic agents.
• Conflicting data exist regarding PBR ligand effects on cell survival and the specificity of their action.
• High drug concentrations used in previous studies questioned the role of PBR in observed toxicities.

Purpose of the Study:

• To investigate the cytotoxicity of PBR ligands FGIN-1-27 and Ro 5-4864 on cancer cell lines.
• To determine if the observed cytotoxicity is mediated by PBR binding.
• To characterize the cell death mechanisms induced by these ligands.

Main Methods:

• Treatment of PBR-expressing SK-N-BE neuroblastoma cells and PBR-deficient Jurkat lymphoma cells with FGIN-1-27 and Ro 5-4864.
• Assessment of cell viability and characterization of cell death pathways (apoptosis vs. necrosis).
• Evaluation of PBR expression in cell lines and PBR-transfected cells.

Main Results:

• Both FGIN-1-27 and Ro 5-4864 demonstrated significant cytotoxicity against both neuroblastoma and lymphoma cells at micromolar concentrations.
• The cytotoxic effects were independent of PBR expression levels in the tested cell lines.
• Ro 5-4864 induced apoptosis in Jurkat cells and necrosis in SK-N-BE cells, with PBR transfection not altering the apoptotic pathway.

Conclusions:

• The cytotoxicity of FGIN-1-27 and Ro 5-4864 is not mediated by the peripheral-type benzodiazepine receptor.
• These PBR ligands are effective cytotoxic agents against various cancer cells, including chemoresistant neuroblastoma and PBR-lacking tumor cells.
• The findings suggest potential for these compounds as novel chemotherapeutic drugs with mechanisms independent of PBR.